H.C. Wainwright lowered the firm’s price target on Rani Therapeutics to $9 from $13 and keeps a Buy rating on the shares post the Q2 report. The target cut reflects the equity dilution from the most recent financing, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RANI:
- Rani Therapeutics reports Q2 EPS (26c), consensus (32c)
- Rani Therapeutics initiated with an Outperform at Oppenheimer
- Rani Therapeutics to Participate in August Investor Conferences
- Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering
- Rani Therapeutics to sell 2.8M shares at $3.08 in registered diect offering